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Background and aims: To assess the efﬁcacy and safety of K-877 (Pemaﬁbrate), a novel selective perox-
isome proliferator-activated receptor a modulator (SPPARMa) that possesses unique PPARa activity and
selectivity, compared with placebo and fenoﬁbrate in dyslipidaemic patients with high triglyceride (TG)
and low high-density lipoprotein cholesterol (HDL-C) levels.
Methods and results: This study was a double blind, placebo-controlled, parallel-group 12-week clinical
trial. The study randomized 224 patients to K-877 0.025, 0.05, 0.1, 0.2 mg BID, fenoﬁbrate 100 mg QD, or
placebo (1:1:1:1:1:1) groups. Least squares mean percent changes from the baseline TG levels
were 30.9%, 36.4%, 42.6%, 42.7% for the K-877 0.025, 0.05, 0.1, 0.2 mg BID respectively (p < 0.001),
which were greater than that of the fenoﬁbrate 100 mg QD (29.7%, p < 0.001) group. Statistically
signiﬁcant improvements from the baseline HDL-C, very-low-density lipoprotein cholesterol, chylomi-
cron cholesterol, remnant lipoprotein cholesterol, apolipoprotein (apo) B (apoB), and apoC-III were also
observed in the K-877 groups. The incidence of adverse events (AEs) in the K-877 groups (32.4e56.8%)
was comparable to those in placebo (47.2%) and fenoﬁbrate 100 mg QD (56.8%); adverse drug reactions
(ADRs) in the K-877 groups (2.7e5.4%) were less than those in placebo (8.3%) and fenoﬁbrate 100 mg QD
(10.8%) groups.
Conclusion: In dyslipidaemic patients with high TG and low HDL-C, K-877 improved TG, HDL-C, and
other lipid parameters without increasing AEs or ADRs, compared to placebo and fenoﬁbrate. K-877 can
be expected to improve atherogenicity and to be a new beneﬁcial treatment for dyslipidaemic patients.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).), shizu@imed2.med.osaka-u.
araki@gpo.kumamoto-u.ac.jp
ote), suganami@kowa.co.jp
(J.-C. Fruchart), kodama@
Ireland Ltd. This is an open access1. Introduction
Cardiovascular diseases (CVDs) are the leading cause of mor-
tality andmorbidity, accounting for 31% of all deaths worldwide [1].
Of all deaths due to CVD, approximately 80% were due to coronary
heart disease (CHD) or stroke. Dyslipidaemia is one of the majorarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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and obesity [1].
Numerous studies show that blood cholesterol-lowering ther-
apy reduces the occurrence of atherosclerotic cardiovascular dis-
ease (ASCVD) [2]. Meta-analysis of large clinical trials revealed that
statins reduce the risk of ASCVD by approximately 20e30% [3]. This
suggests that 70% of risk remains even after treatment of high low-
density lipoprotein-cholesterol (LDL-C) by statins [4]. To further
reduce this risk, other lipid risk factors such as high levels of tri-
glycerides (TG), low high-density lipoprotein cholesterol (HDL-C),
and high non-HDL-C are potential viable targets for non-statin
treatment. Many guidelines recommend treatment with bile acid
sequestrants, nicotinic acids, ﬁbrates, and n-3 (omega-3) fatty acids
to manage these factors [5]. Fibrates or nicotinic acids are partic-
ularly recommended to manage elevated TG and low HDL-C levels.
According to sub-analyses of recent trials, the use of ﬁbrate resulted
in favourable cardiovascular outcomes in patients with high TG and
low HDL-C levels [6]. Moreover, a meta-analysis revealed that
ﬁbrates could reduce CV risks [7].
Peroxisome proliferator-activated receptors (PPARs) are a su-
perfamily of nuclear hormone receptors that form complexes with
the retinoid X receptor (RXR) and bind to PPAR response elements
(PPRE) on DNA. There are three different types of PPAR (a, d, and g)
[8]. In general, the activation of PPARa is associated with the
attenuation of lipid and/or glucose metabolic dysfunction, inﬂam-
mation, atherosclerosis, and vascular dysfunction. With regard to
TG metabolism, PPARa targets genes that express proteins such as
apolipoprotein (apo) CIII, apoAV and lipoprotein lipase (LPL),
thereby reducing the amount of free fatty acids utilized for the
synthesis and secretion of apoB-containing lipoproteins. With re-
gard to HDL metabolism, PPARa targets apoAI, apoAII, scavenger
receptor-BI (SR-BI), and ATP-binding cassette transporter A1
(ABCA1), thereby increasing HDL production and stimulating
reverse cholesterol transport [9].
K-877 (Pemaﬁbrate) is a novel member of the selective PPARa
modulator (SPPARMa) family [10] that was designed to have a
higher PPARa agonistic activity and selectivity than existing PPARa
agonists (such as ﬁbrates) [11]. In the present study, we report the
results of a K-877 phase 2 study in dyslipidaemic patients with high
TG and low HDL-C levels.
2. Methods
2.1. Patients/study design and participants
We undertook this randomized, double blind, active- and
placebo-controlled phase 2 trial at 19 sites in Japan. The study took
place between November 22, 2010, and July 7, 2011.
Men and postmenopausal women aged 20e74 years who had a
history of documented dyslipidaemia and plasma TG of 200 mg/dL
or higher as well as HDL-C less than 50 mg/dL in men or 55 mg/dL
in women, during two consecutive evaluations were eligible. Major
exclusion criteria were as follows: TG of 500 mg/dL or more during
two consecutive evaluations; patients who needed additional drug
treatment for dyslipidaemia during the study period; type 1 dia-
betes or poorly controlled type 2 diabetes (HbA1c of 8.4% or more);
poorly controlled hypertension (systolic blood pressure of
160 mmHg or more or diastolic blood pressure of 100 mmHg or
more); poorly controlled thyroid disorder; mild or more severe
renal disorder (serum creatinine of 1.5 mg/dL or more); current or
past history of hepatic impairment; aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) levels more than 2-fold
higher than the upper limit of the reference range; current gall-
bladder disease or a history of cholelithiasis; ﬁbrinogen level less
than the lower limit of the reference range; alcohol or drugaddiction; habitual excessive alcohol consumption (g-glutamyl
transferase (g-GT) levels 2.5-fold higher than the upper limit of
reference range). The concomitant use of drug treatment for dys-
lipidaemia was prohibited. Patients were ineligible, if they received
these drugs within four weeks prior to the ﬁrst screening visit.
Thiazolidinediones, insulin products and derivatives, adrenal cor-
ticosteroids, protease inhibitors, protein anabolic hormones, and
luteum hormones were also prohibited during the study period
owing to their potential effects on dyslipidaemia. Patients were
instructed to maintain their diet, exercise, and pharmacological
therapy during the study period.
The study protocol and amendment were approved by the in-
dependent ethic committee or institutional review board before
the commencement of study. The study was conducted in accor-
dance with the principle of the Declaration of Helsinki, and under
the guidelines of Good Clinical Practice and the International
Conference on Harmonization. All study participants provided
written informed consent prior to involvement. This trial is regis-
tered with JAPIC Clinical Trials Information, number Japic CTI-
101331.
2.2. Procedures
Fig. S1 shows the study design, depicting the duration of each
period and timing of study visits. Fig. S2 shows the disposition of
the patients. Patient demographics were assessed or recorded
during the screening period. After randomization (week 0), pa-
tients were randomly assigned, in a 1:1:1:1:1:1 ratio, to treatment
with either K-877 at a dose of 0.025, 0.05, 0.1, or 0.2 mg BID (twice
daily; 0.05, 0.1, 0.2, and 0.4 mg/day, respectively), fenoﬁbrate (LIP-
IDIL®) at a dose of 100 mg QD (once daily), or matching placebo.
LIPIDIL® 100 mg micronized capsule had been marketed as equiv-
alent to the LIPIDIL® 80 mg tablet. Randomization was done with a
central computer-controlled systemwith stratiﬁcation according to
the HDL-C value at the ﬁrst screening visit to avoid imbalance. This
study comprised a screening period of a maximum of eight weeks
before the commencement of the treatment, and then a 12-week,
double-blind treatment period followed by a 4-week follow-up
period. During the screening and treatment period, patients
visited the site for at least two screening visits, and at baseline
(randomization visit i.e. week 0), week 2, 4, 8, and 12, at which
fasting (10 h) blood and urine samples were collected for the
assessment of clinical laboratory ﬁndings, including lipids. Study
eligibility was determined by the laboratory data sampled at two
screening visits. Following the treatment period, patients stopped
taking the study drug and a follow-up visit was performed after
four weeks (at week 16) for safety assessment.
At each treatment visit, patients received press-through-
packages of the study drug except at week 12, and were instruc-
ted to take one tablet and one capsule after breakfast and one tablet
after dinner.
2.3. Clinical laboratory and lipoprotein analysis
Lipoprotein level was measured by the direct enzymatic
method; apolipoprotein level was measured by the immunoassay
method. Other laboratory parameters were analysed by a stan-
dardized laboratory method (all measurements were done by LSI
Medience Corporation, Japan, or its afﬁliates). Fibroblast growth
factor 21 (FGF21) level was measured by enzyme-linked immuno-
sorbent assay (ELISA) (Bio Vendor HUMAN FGF-21 ELISA). The
concentration of TG and cholesterol, phospholipid, and free
cholesterol contained in lipoprotein fractions were measured by
the high-performance liquid chromatography (HPLC) (Lip-
oSEARCH©, Skylight Biothech, Japan) method. HPLC measured TG,
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lipoprotein subfractions divided by particle diameters: two chylo-
micron (CM); ﬁve very-low-density lipoprotein (VLDL) (comprising
large, medium, and small VLDL subclasses); six LDL (comprising
large, medium, small and very small subclasses); seven HDL
(comprising very large, large, medium, small, and very small sub-
classes) [12].
2.4. Statistical analysis
A sample size of 192 patients, with 32 patients in each group,
ensured at least 90% power to detect a 30% reduction in TG levels
from the baseline to week 12 using a Dunnett's test with an alpha
level of 0.05. In this calculation, we assumed a standard deviation of
30 for percent change of TG reduction and a dropout rate of 10%.
SAS (version 9.2) was used for analysis. The primary efﬁcacy anal-
ysis was performed according to the per-protocol-set on data from
all patients who were randomized to the treatment group and had
at least one study treatment, both values of baseline, and at least
one post-baseline visit without deviations, which affect efﬁcacy
evaluation. The primary safety analysis was performed according to
safety-analysis-set on data from all patients who were randomized
to the treatment group and had at least one study drug. All analyses
of primary efﬁcacy and safety parameters were performed ac-
cording to pre-speciﬁed statistical analysis plan.
We analysed the primary endpoint using an ANCOVA model
with the baseline value as a covariate. The primary efﬁcacy
endpoint was the percent change of TG at the end of the treatment
period from baseline. Primary analysis of the primary endpoint was
an evaluation of the dose-dependent relationship of all K-877
groups, including the placebo group, using the maximum contrast
method. Secondary analysis of the primary endpoint was investi-
gation of the superiority of the K-877 group compared to placebo
by Dunnett's test, only if statistical signiﬁcance was conﬁrmed
during primary analysis. Exploratory analysis of the primary
endpoint was the difference of K-877 in each group and fenoﬁbrate
using the ANCOVA model. The primary safety endpoint was the
event ratio of adverse events and adverse reactions. One sample t-
test or Wilcoxon signed rank test was used to assess the difference
from baseline to week 12, and the two sample t-test or Wilcoxon
rank sum test were used to assess a group difference.
3. Result
A total of 224 patients were randomly assigned to treatment.Table 1
Demographics and clinical characteristics at baseline (Per-protocol-set).
K-877
Placebo 0.025 mg BID 0.05 m
n 35 34 37
Age, years 48.7 (9.0) 50.9 (9.9) 50.0
Sex, male n (%)a 34 (97.1) 29 (85.3) 36
Weight, kg 77.02 (9.38) 75.95 (11.84) 76.01
BMI, kg/m2 26.86 (2.66) 26.45 (3.26) 26.80
Type 2 DM, n (%)a 4 (11.4) 5 (14.7) 5
Hypertension, n (%)a 9 (25.7) 10 (29.4) 11
Fatty liver, n (%)a 8 (22.9) 8 (23.5) 4
TG, mmol/L 3.49 (1.47) 3.77 (2.49) 3.33
HDL-C, mmol/L 1.04 (0.16) 1.05 (0.21) 1.06
LDL-C,b mmol/L 3.32 (0.76) 3.30 (0.85) 3.16
Non HDL-C, mmol/L 4.78 (0.77) 4.70 (0.93) 4.56
Mean (SD).
a The number (percentage) of patients.
b Ultracentrifugation.Table 1 shows the demographics and clinical characteristics of pa-
tients at baseline. Of 224 patients, 10 patients were excluded from
the per-protocol-population owing to concomitant use of pro-
hibited treatment, missing TG baselines or last evaluation points;
thus, per-protocol-population comprised 214 patients. One patient
who received fenoﬁbrate 100 mg QD discontinued the study owing
to liver function abnormalities; thus, a total of 213 patients
completed the study. Including TG and HDL-C, demographics and
baseline clinical characteristics were similar across all dosing
groups.
All treatments except placebo reduced the TG level (Fig. 1A,
Fig. S3A). TG levels in the K-877 group decreased in a dose-
dependent manner, with TG reduction plateauing at 0.1 mg BID,
although a marked reduction was observed at higher doses.
Compared to fenoﬁbrate, all K-877 dosing groups demonstrated
greater TG reduction, although the differences were not statistically
signiﬁcant.
All treatments except the placebo increased HDL-C level (Fig. 1B,
Fig. S3B). There was a dose-dependent increase in the K-877 group,
with the HDL-C increase plateauing at 0.05mg BID, although 0.2mg
BID increased HDL-C the most in all groups. Compared to fenoﬁ-
brate, the increase in HDL-C was larger in K-877 0.05, 0.1, and
0.2 mg BID, but the difference was not statistically signiﬁcant.
The percent changes or changes from baseline of other key pa-
rameters are summarized in Table 2 and Table S1. The reductions of
non HDL-C, VLDL-C, remnant lipoprotein cholesterol (RemL-C),
apoB48, and apoCIII were statistically signiﬁcant in the K-877
groups and fenoﬁbrate, compared to placebo. The reduction of
VLDL-C was statistically signiﬁcant in K-877 0.1 and 0.2 mg BID
groups compared to fenoﬁbrate. All doses of K-877 and fenoﬁbrate
signiﬁcantly increased levels of apoAI and apoAII. Compared to
fenoﬁbrate, K-877 0.2 mg BID showed greater increases of apoAI
and apoAII levels. A slight increase from baseline in LDL-C was
observed in the K-877 groups and fenoﬁbrate group, with the
change in both groups being comparable. As part of the post hoc
analysis, we evaluated the relationship between the baseline levels
of TG or LDL-C and the change in LDL-C (Figs. S4 and S5). The
magnitude of change of LDL-C from baseline positively correlated
with baseline TG and negatively correlated with baseline LDL-C.
The subclasses of lipoproteins were analysed by HPLC (Fig. 2,
Table S2). Dose-related reductions from baseline were observed in
the small and very small LDL categories in the K-877 groups while
dose-dependent increases from baseline were observed in the
small and very-small HDL categories in the K-877 groups.
FGF21, a hormonal regulator, signiﬁcantly increased fromFenoﬁbrate
g BID 0.1 mg BID 0.2 mg BID 100 mg QD
36 36 36
(12.4) 48.8 (10.7) 47.8 (12.8) 51.1 (11.5)
(97.3) 33 (91.7) 34 (94.4) 33 (91.7)
(13.53) 80.76 (14.07) 75.08 (11.52) 75.47 (10.96)
(3.82) 27.84 (3.72) 26.51 (3.56) 26.63 (3.01)
(13.5) 4 (11.1) 5 (13.9) 4 (11.1)
(29.7) 10 (27.8) 7 (19.4) 8 (22.2)
(10.8) 6 (16.7) 8 (22.2) 10 (27.8)
(1.25) 3.29 (1.35) 3.42 (2.36) 3.68 (2.31)
(0.18) 1.06 (0.19) 1.07 (0.18) 1.04 (0.19)
(0.95) 3.39 (0.98) 3.76 (0.93) 3.47 (0.91)
(0.95) 4.75 (0.94) 5.13 (0.98) 4.96 (1.01)
Fig. 1. Percent change from baseline at 12 weeks (A) TG, (B) HDL-C. Least Squares Mean. Error bars represent standard error (SE). ***p < 0.001 vs baseline, yyp < 0.01, yyyp < 0.001 vs
Placebo (Dunnett), ###p < 0.001 vs Fenoﬁbrate.
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Statistically signiﬁcant increases were observed in K-877 0.05, 0.1,
and 0.2 mg BID compared to that of placebo and fenoﬁbrate groups.
The overall frequency of adverse events was comparable across
all groups. The most frequently observed adverse events included
seasonal allergy and nasopharyngitis (n ¼ 16 for both). In total,
there was no dose-dependent increase of adverse events or adverse
drug reactions in the K-877 groups. The fenoﬁbrate and placebo
groups were associated with a slightly higher frequency of adverse
drug reactions than the K-877 groups. The most frequently
observed adverse drug reactions with fenoﬁbrate were clinical
laboratory abnormalities. Adverse events and laboratory abnor-
malities with respect to liver and muscle enzymes are summarized
in Table 3. The rate of elevated AST levels in the K-877 groups was
similar to that of placebo, while fenoﬁbrate group had higher levels
of AST than the other groups. The rate of elevated ALT levels in the
K-877 groups was lower than that of the placebo or fenoﬁbrate
group. One patient, who was assigned to fenoﬁbrate group, dis-
continued the study owing to liver function abnormalities (liver
enzyme increase). There was no case of elevated CK more than two
times higher the upper limit of the reference range.4. Discussion
In the present study, we ﬁrst report that K-877 signiﬁcantly
reduced TG and increased HDL-C levels comparedwith the placebo.
The effects of K-877 in reducing TG and increasing HDL-C appear
to be the most potent among this class of drugs with PPARa
agonistic activity. Its relative efﬁcacy is superior to fenoﬁbrate by
three orders of magnitude, almost completely corroborating its
relative potency as a PPARa agonist evaluated in in vitro assays [10].
The TG reduction produced by 100mg QD fenoﬁbratewas as potent
as that of 0.025 and 0.05 mg BID K-877, while the HDL-C-raising
effects of 100 mg QD fenoﬁbrate was as potent as 0.05 and
0.1 mg BID K-877. Therefore, K-877may affect TG metabolismmore
favourably than HDL metabolism, although these differences were
not statistically signiﬁcant. In parallel, lipid parameters closely
related to TG metabolism, such as VLDL-C, apoB48, RemL-C, andapoCIII, were more favourably affected than lipid parameters
closely related to HDLmetabolism such as apoAI and apoAII. Recent
human genetic discoveries implicate the role of triglycerides and
triglyceride-rich lipoproteins in the development of cardiovascular
risk [13] and show that ApoCIII and ApoAV have a signiﬁcant in-
ﬂuence on the risk of CAD. Together with the results of longitudinal
studies showing that remnant lipoproteins are strong risk factors
for CHD [14], the preferential effects of K-877 on RemL-C, which
reﬂects the combination of VLDL and chylomicron remnants, and
apoB48, a marker for chylomicron remnants, may suggest that K-
877 has anti-atherogenic potential. As reported previously, the
transactivation of genes such as LPL, apoAI, apoAII, ABCA1, ABCG1,
and SR-BI, as well as the transrepression of genes such as apoCIII,
which antagonizes LPL action, may underlie these effects [9]. It is
plausible that K-877more preferentially affects genes governing TG
metabolism than those governing HDL metabolism. These phe-
nomena of differential effects between K-877 and fenoﬁbrate were
reported for other hepatic genes in mice and humans [15].
K-877 appears to increase LDL-C, albeit weakly, in the present
study. However, this LDL-C raising effect was not accompanied by
increases in apoB or non-HDL-C levels, suggesting that K-877 in-
creases LDL-C not by increasing the particle number of LDL, but
rather by increasing the cholesterol content of LDL. It is important
to note that LDL consists of multiple classes with different
atherogenic potentials. It is well known that an increase in small,
dense LDL is associated with an increased risk for developing CHD.
The results of the subfractionation of LDL by HPLC show that the
large and medium LDL subfractions increased in the current study,
which are conceivably less atherogenic. On the other hand, the
more atherogenic small and very small LDL decreased. A similar
increase in LDL-C was reported for LY518674, which is also a potent
and selective PPARa agonist, in patients with atherogenic dyslipi-
daemia [16]. As in the case with LY518674, the increase in LDL-C
with K-877 positively correlated with baseline TG. This relation-
ship can be largely explained by the precursor-product relationship
between VLDL and LDL; LDL is produced as an ultimate product of
the lipolytic conversion of VLDL [17]. Further studies are warranted
to deﬁne themechanisms underlying the variability of the effects of
Table 2
Change fromWeek 0 of key secondary endpoint (Per-protocol-set).
K-877 Fenoﬁbrate
Placebo 0.025 mg BID 0.05 mg BID 0.1 mg BID 0.2 mg BID 100 mg QD
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
TC, mmol/L Week 0 35 5.82 (0.79) 34 5.74 (0.95) 37 5.61 (1.01) 36 5.81 (1.03) 36 6.20 (1.00) 36 6.00 (1.08)
% Change 0.1 (9.8)# 2.7 (11.4) 6.5 (11.9)**y 7.0 (11.3)***y 5.3 (12.9)* 6.0 (11.8)**y
non HDL-C, mmol/L Week 0 35 4.78 (0.77) 34 4.70 (0.93) 37 4.56 (0.95) 36 4.75 (0.94) 36 5.13 (0.98) 36 4.96 (1.01)
% Change 0.7 (12.8)## 5.8 (12.4)* 11.8 (14.0)***yyy 12.2 (13.8)***yyy 10.5 (14.2)***yyy 10.1 (14.2)***yy
VLDL-C,a mmol/L Week 0 35 0.98 (0.30) 34 0.92 (0.22) 37 0.97 (0.33) 36 0.96 (0.34) 36 1.00 (0.34) 36 0.96 (0.21)
% Change 13.3 (38.9)### 24.3 (24.0)***yyy 37.3 (26.7)***yyy 43.8 (24.0)***yyy## 48.4 (27.5)***yyy## 25.8 (29.7)***yyy
LDL-C,a mmol/L Week 0 35 3.32 (0.76) 34 3.30 (0.85) 37 3.16 (0.95) 36 3.39 (0.98) 36 3.76 (0.93) 36 3.47 (0.91)
% Change 6.3 (16.2)*# 8.9 (21.3)*y 8.3 (29.4)y 5.0 (28.0) 7.4 (26.5)y 5.3 (23.4)y
RemL-C, mmol/L Week 0 35 0.56 (0.30) 34 0.54 (0.32) 37 0.53 (0.24) 36 0.50 (0.24) 36 0.54 (0.35) 36 0.55 (0.27)
% Change 38.7 (75.7)**### 32.3 (33.8)***yyy 42.8 (29.4)***yyy 48.3 (28.1)***yyy 50.1 (31.8)***yyy 31.8 (35.0)***yyy
apoAI, mg/dL Week 0 35 127.3 (13.9) 34 128.6 (13.5) 37 127.5 (11.1) 36 127.9 (13.4) 36 126.7 (12.4) 36 125.4 (11.6)
% Change 1.0 (8.0)## 2.5 (9.9) 4.6 (9.9)**y 6.0 (9.7)***yy 8.6 (13.9)***yyy 5.6 (8.0)***yy
apoAII, mg/dL Week 0 35 29.75 (3.18) 34 29.24 (3.01) 37 29.65 (3.41) 36 30.07 (3.43) 36 29.94 (3.05) 36 28.79 (3.15)
% Change 1.5 (6.5)### 9.9 (10.5)***yy## 14.4 (11.5)***yyy 21.0 (16.2)***yyy 30.0 (22.1)***yyy## 20.1 (13.0)***yyy
apoB, mg/dL Week 0 35 114.7 (19.8) 34 114.8 (21.1) 37 110.0 (20.9) 36 115.9 (22.5) 36 123.8 (20.0) 36 118.9 (22.5)
% Change 2.0 (9.9) 1.4 (13.6) 8.9 (13.6)***y 7.8 (15.0)** 8.1 (11.6)*** 5.7 (14.4)*
apoB48, mg/mL Week 0 35 11.54 (7.77) 34 11.31 (7.18) 37 10.67 (5.85) 36 11.73 (6.83) 36 10.40 (7.80) 36 12.26 (7.61)
% Change 54.6 (171.1)### 28.4 (43.1)***yyy 43.1 (47.1)***yyy 55.9 (25.6)***yyy 51.2 (29.3)***yyy 37.9 (42.9)***yyy
apoCIII, mg/dL Week 0 35 14.93 (4.59) 34 14.88 (3.46) 37 15.18 (4.72) 36 15.22 (5.63) 36 14.32 (4.37) 36 15.94 (4.86)
% Change 7.9 (27.4)### 22.2 (14.4)***yyy 29.0 (18.9)***yyy 34.6 (17.7)***yyy 33.4 (19.2)***yyy 27.2 (18.9)***yyy
Glucose, mmol/L Week 0 35 6.20 (1.15) 34 6.12 (1.06) 37 5.88 (0.87) 36 6.29 (1.19) 36 6.07 (1.27) 36 6.16 (1.48)
Change 0.20 (0.78)## 0.19 (0.45)*## 0.04 (0.49) 0.28 (0.64)*yy 0.06 (0.60) 0.32 (1.08)yy
Insulin, pmol/L Week 0 34 78.46 (45.99) 31 77.94 (41.79) 37 73.07 (35.35) 36 122.87 (151.86) 35 78.26 (72.31) 34 80.01 (45.97)
Change 5.45 (24.77) 4.57 (35.51) 8.58 (25.18)* 55.50 (145.21) *yyy## 14.52 (47.75) 3.45 (59.49)
HOMA-R Week 0 34 3.22 (2.29) 31 3.05 (2.07) 37 2.76 (1.42) 36 5.25 (7.58) 35 3.00 (2.85) 34 3.24 (2.31)
Change 0.46 (1.49) 0.24 (1.72) 0.33 (0.93)* 2.65 (7.35)*yyy## 0.50 (2.02) 0.38 (2.76)
Log FGF21, Log(pg/mL) Week 0 35 5.74 (0.57) 34 6.01 (0.76) 37 5.74 (0.50) 36 5.93 (0.42) 36 5.94 (0.73) 36 5.96 (0.56)
Change 0.13 (0.36)* 0.15 (0.59) 0.66 (0.62)***yyy### 0.42 (0.46)***y# 0.78 (0.54)***yyy### 0.16 (0.45)*
*p < 0.05, **p < 0.01, ***p < 0.001 vs Week 0 (one sample t-test).
yp < 0.05, yyp < 0.01, yyyp < 0.001 vs Placebo (two sample t-test).
#p < 0.05, ##p < 0.01, ###p < 0.001 vs Fenoﬁbrate 100 mg/day (two sample t-test).
a Ultracentrifugation.
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Fig. 2. Subclass analysis of lipoproteins by HPLC (A) LDL, (B) HDL. Mean. Error bars represent standard deviation (SD). *p < 0.05, **p < 0.01, ***p < 0.001 vs Week 0 (one sample t-
test). yp < 0.05, yyp < 0.01, yyyp < 0.001 vs Placebo (two sample t-test). #p < 0.05, ##p < 0.01, ###p < 0.001 vs Fenoﬁbrate 100 mg/day (two sample t-test).
Table 3
Summary of adverse events (Safety-analysis-set).
K-877 Fenoﬁbrate
Placebo 0.025 mg BID 0.05 mg BID 0.1 mg BID 0.2 mg BID 100 mg QD
n ¼ 36 n ¼ 37 n ¼ 37 n ¼ 38 n ¼ 39 n ¼ 37
AEs 17 (47.2) 21 (56.8) 12 (32.4) 18 (47.4) 16 (41.0) 21 (56.8)
Discontinuations because of AEs 0 0 0 0 0 1 (2.7)
Seasonal allergy 2 (5.6) 2 (5.4) 4 (10.8) 3 (7.9) 3 (7.7) 2 (5.4)
Nasopharyngitis 0 2 (5.4) 3 (8.1) 4 (10.5) 2 (5.1) 5 (13.5)
Upper respiratory tract inﬂammation 3 (8.3) 2 (5.4) 1 (2.7) 2 (5.3) 2 (5.1) 2 (5.4)
AEs leading to withdrawal 0 0 0 0 0 1 (2.7)
Serious AEs 0 1 (2.7) 0 0 1 (2.6) 0
ADRs 3 (8.3) 2 (5.4) 1 (2.7) 2 (5.3) 2 (5.1) 4 (10.8)
AST > upper limit of normal 3 (8.3) 0 2 (5.4) 3 (7.9) 0 9 (24.3)
ALT > upper limit of normal 5 (13.9) 2 (5.4) 0 4 (10.5) 1 (2.6) 5 (13.5)
CK > upper limit of normal  2 1 (2.8) 0 0 0 0 0
sCr > 1.5 mg/dL 0 0 0 0 1 (2.6) 0
Fibrinogen < lower limit of normal 0 0 0 0 1 (2.6) 0
The number (percentage) of patients.
AE: adverse event, ADR: adverse drug reaction, sCr: serum creatinine.
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With regard to the effects on HDL-C, the K-877- and/or
fenoﬁbrate-induced increases in HDL-C were accounted for by the
changes in the three smaller subpopulations of HDL (medium,
small, and very small). Generally, the smaller subpopulation of
particles such as HDL3 is more closely associated with protection
against CHD [18]. Therefore, the current ﬁndings, that K-877 spe-
ciﬁcally increased the smaller subpopulations of HDL, support the
possibility that these K-877-induced alterations in HDL are pro-
tective against atherosclerosis.
The effects of K-877 on FGF21 are also noteworthy. FGF21 is amember of FGF family, which has insulin-sensitizing activity and is
produced mainly by the liver in response to starvation and/or
ketogenic diets [19]. Fibrates increase plasma FGF21 by activating
PPARa [20,21]. Thus, it is conceivable that effects of K-877 on the
metabolism of glucose and lipids are mediated at least in part by
the effect of FGF21. Based on our results, K-877 increases FGF21
more preferentially than fenoﬁbrate. However, we did not ﬁnd a
signiﬁcant difference in body weight and other parameters for
glucose tolerance. Therefore, the magnitude of the preferential
increase of FGF21 by K-877 may not be sufﬁcient to cause favour-
able metabolic alterations in terms of glucose tolerance.
S. Ishibashi et al. / Atherosclerosis 249 (2016) 36e4342In general, both K-877 and fenoﬁbrate were well tolerated
without obvious safety concerns. Fibrates are known to increase
plasma levels of homocysteine and creatinine, both of which
potentially mitigate the other anti-atherogenic effects of ﬁbrates
[22,23].
Based on the present results, K-877 did not increase plasma
creatinine, and only increased plasma homocysteine modestly at
the 0.2 mg BID concentration (Table S3). Therefore, K-877 may be
more favourable than fenoﬁbrate in terms of anti-atherogenecity.
These effects of K-877 support the SPPARMa concept that sepa-
rates the beneﬁt of the PPARa agonists from their unfavorable ef-
fects. Furthermore, K-877 signiﬁcantly decreased plasma
concentrations of liver enzymes (ALT and g-GT), while fenoﬁbrate
did not (Table S3). Recently, the alleviation of hepatic steatosis by
GFT505, a PPARa/d dual agonist, has been reported in mice [24].
Conceivably, K-877 may have comparable efﬁcacy and can be used
to treat NAFLD and/or NASH to inhibit the development of hepa-
tocellular carcinoma.
This study has several potential limitations. First, we excluded
patients who were currently receiving treatments for dyslipidae-
mia, including statins. Moreover, there were several strict exclusion
criteria for liver impairment, renal impairment, and diabetes mel-
litus, all of which are frequently observed in patients with dysli-
pidaemia in clinical practice. Second, the duration of the treatment
period was 12 weeks, which is a relatively short for the evaluation
of chronic diseases. A longer study period will be needed to
investigate the risk to beneﬁt balance. Third, our study population
consisted of only Japanese people; thus, the study results may not
be applicable to patients of other ethnicities. Finally, fenoﬁbrate
100 mg, which was used as an active comparator in this study, was
half the maximal dose that is allowed for use. Thus, higher doses of
fenoﬁbrate will be needed as a point of comparison to demonstrate
the superiority of K-877 over fenoﬁbrate.
In conclusion, K-877 improved TG, HDL-C, and other lipid pa-
rameters in Japanese patients with dyslipidaemia with high TG and
low HDL-C levels. Unlike other PPARa agonists, K-877 reduced the
plasma levels of liver enzymes (i.e. ALT and g-GT) and did not
adversely affect serum creatinine or homocysteine. Taken together,
these results strongly support that K-877 can be developed as a
SPPARMa with an excellent efﬁcacy and safety proﬁle.
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